A white paper by Health Strategies Group, an Eversana company, which is the leading independent provider of global services to the life sciences industry.
This whitepaper assesses the current state of the large molecule sector, and how it may be able to learn from the small molecule industry in terms of its supply chain support infrastructure, as well as its acquisition of staff and the adoption of PAT.
The American Health Policy Institute (AHPI) released “’Tipping Points’ of Employer-Sponsored Health Insurance,” which examines various factors that could impact broad-based employer-provided health coverage.
The American College of Rheumatology published a new white paper, “The Science Behind Biosimilars – Entering a New Era of Biologic Therapy,” providing a comprehensive overview of the scientific, clinical, economic and prescribing issues pertaining to biosimilar use, including efficacy, competition and drug pricing.
ProMIS Neurosciences Inc., a biotechnology company focused on the discovery and development of precision treatments for neurodegenerative diseases, announced it has issued a new scientific white paper entitled: ‘Not all Amyloid Beta Therapeutics are Created Equal’.
In this white paper, PMC contends that most value assessment frameworks could unintentionally undermine the health care community’s push toward more personalized care.
With the focus shifting away from the end reporting, companies have continued to invest in systems and processes that manage “upstream” relationships with healthcare providers and consultants, recognizing that the greater compliance risks center around these relationships than on the reported spend itself.
A combination of regulatory conditions, shifts in physician workplace demographics, and an increased reliance of highly specialized sales personnel has steadily eroded the traditional sales reps’ responsibilities and ability to manage the HCP practice relationship as a true SPOC.
The good news … is that innovation is addressing diseases with high-unmet need such as oncology, autoimmune diseases, and central nervous system (CNS) disorders. But, there is a complicating factor in the economic story: the patient population benefiting from launch brands is becoming smaller.
The white paper explores trends and market forces affecting organized provider groups (OPGs) and identifies opportunities for pharmaceutical manufacturers to partner with OPGs to develop mutually beneficial programs addressing areas of shared interest.